Search Results 161-170 of 19328 for prostate cancer
Eye melanoma; Esophageal cancer; Head and neck cancers; Liver cancer; Lung cancer; Lymphoma; Pancreatic cancer; Pituitary gland tumors; Prostate cancer; Sarcoma ...
... prostate cancer tissue. This will provide data that can be used to identify genetic marker profiles to diagnose and provide prognosis for prostate cancer.
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study. Print details.
The primary hypotheses are that the TULSA-Procedure is safe and effective treatment of intermediate grade prostate cancer over 2 years. The primary endpoint ...
Prostate cancer that's detected early — when it's still confined to the prostate gland — has a better chance to be successfully treated, so it's important that ...
The purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation ...
A new study at Mayo Clinic is using genomic sequencing to develop customized treatments for men with castration-resistant prostate cancer, a progressive and ...
... cancer cells survive after androgen ablation, the most common therapy for advanced prostate cancer. Prostate cancer is initially an androgen-dependent tumor.
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of ...
Each year about 90,000 men seek treatment for recurrent prostate cancer, and evaluating them for recurrence is a major challenge.
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Benefactor support fuels Mayo Clinic’s groundbreaking research. Make a gift today to help us save lives.